法国Polyplus-transfection 
Polyplus-transfection SA 是一家生物科技公司，致力于在研究、生物生产和治疗领域开发、推广和销售创新型核酸体内、体外和离体传输解决方案。该公司靠近法国东部的斯特拉斯堡大学 (University of Strasbourg)，自2002年起通过 ISO 9001 认证，通过全球分销商网络提供其专有的多种基因、寡核苷酸和 siRNA 转染试剂。在世界范围内，越来越多的临床试验采用 Polyplus 试剂。此外，Polyplus-transfection 还拥有多项专利和许可证，包括独创的治疗 siRNA 传输方法。

Polyplus-transfection是一家生命科学公司，致力于转染试剂研发和销售。其中包括基因，寡核苷酸和SiRNA的体内和体外转染，以及蛋白质和抗体的体外转染。
Polyplus-transfection公司的主要使命是担当科研实验室、生物技术公司和制药公司可靠的技术合作伙伴。公司的出发点是为科研者提供高质量的研究工具和技术支持。鉴于Polyplus-transfection公司的发展，产品，以及销售情况，2002年，公司被授予国际标准ISO 9001：2000证书。
Polyplus产品：
jetPEI：转染多种已经建系的贴壁细胞、悬浮细胞及原代细胞
INTERFERin：体外siRNA转染试剂
in vivo jetPEI：体内DNA、siRNA转染试剂
PULSin：体外蛋白、抗体转染试剂
jetPEI-Macrophage：转染巨噬细胞和树突状细胞
jetPEI-Hepatocyte：转染肝实质细胞
jetPEI-RGD：转染上皮及内皮细胞
jetPEI-HUVEC：转染人脐静脉内皮细胞
jetPEI-FluoF : 荧光素标记的jetPEI
jetPEI-FluoR : 四甲基罗丹明标记的jetPEI
in vivo-jetPEI-FluoF : 荧光素标记的in vivo-jetPEI
in vivo-jetPEI-FluoR : 四甲基罗丹明标记的in vivo-jetPEI
in vitro-jetPEI-Biotin
in vivo-jetPEI-Biotin

Polyplus-transfection is a research-focused biotechnology company developing and marketing innovative solutions for transfection and therapies based on nucleic acid delivery. 

Technology

Transfection allows the introduction of nucleic acids, such as a gene or small interfering RNA (siRNA), into cells using chemical compounds. The technique is widely used in experimental research and in protein production.
Introducing a gene into a cell nucleus triggers the expression of the corresponding protein. Conversely, transferring siRNA will block the production of a protein.
Inappropriate gene expression is the root cause of numerous diseases. As a result, the ability to control those genes through gene therapy or RNA interference opens up new therapeutic approaches where efficient intra-cellular drug transfer is key to success.

Research & Development

Using its know-how in nucleic acid delivery, the R&D department at Polyplus-transfection is focused on the development of innovative synthetic compounds designed to take account of the latest advances in the transfer of biomolecules, especially the in vivo delivery of small interfering RNA. Polyplus-transfection is one of the technology leaders in the transfection market.
Polyplus-transfection has established a number of R&D partnerships with biotechnology companies involved in therapeutics. It also plays an active role in European research networks such as GIANT (Gene therapy, and Integrated Approach to Neoplastic Treatment) and RIGHT (RNA Interference Technology as Human Therapeutic Tool).
Polyplus-transfection recently extended its field of expertise to the development of new cationic oligonucleotides, ZNA™, for molecular biology and diagnostics.

Product Portfolio

Polyplus-transfection has been selling its products and services through an international distribution network since 2001. Its customers include biotechnology companies, big pharma and research laboratories. The company established a sales subsidiary in the USA in 2006.
The company also offers high quality consultancy and personalized scientific assistance. Polyplus-transfection has given a high priority to quality management since 2002 when it acquired the ISO 9001:2000 certification.
Polyplus-transfection markets transfection agents for research:
o jetPEI™: in vitro gene transfection
o in vivo-jetPEI™: in vivo nucleic acid transfection
o Fecturin™ : protein and virus production in synthetic media
o INTERFERin™: in vitro siRNA transfection
o FectoFly™: in vitro transfection in insect cells
o PULSin™: in vitro delivery of proteins, antibodies and peptides
Polyplus-transfection also offers GMP-compliant reagents. The company has acquired a widely-acknowledged expertise in the regulatory and technical issues regarding clinical trials using its products. Such trials are currently being carried out in Israel and the USA (cancer therapeutics) and in Hungary, Sweden and Germany (HIV immune therapy).

Current developments

o Setting up of the Polyplus in vivo Consortium, an international network, run by Polyplus-transfection, for scientists and clinicians using Polyplus-transfection compounds in gene therapy. The network aims to encourage and accelerate the development of new clinical projects.
o Development of a novel design of siRNA in order to improve siRNA delivery in vivo, the “STICKY SIRNA™”. By including longer overhangs, the STICKY SIRNA™ (ssiRNA™) are able to form concatemers in the presence of in vivo-jetPEI™, thereby mimicking the structure of DNA and thus enhancing siRNA delivery (Bolcato-Bellemin (2007) PNAS 104:16050).
o Development of a new class of modified oligonucleotides, ZNA™, which show a greater affinity for nucleic acids than standard oligonucleotides. By enhancing the sensitivity and the efficiency of hybridization, these versatile ZNA™ are new promising tools for nucleic acid detection methods and for molecular diagnostic applications.